Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
作者信息
Moertel Christopher L, Hirbe Angela C, Klesse Laura J, Nghiemphu P Leia, Babovic-Vuksanovic Dusica, Gershon Timothy R
机构信息
Christopher L. Moertel, MD, Department of Pediatrics, University of Minnesota, Minneapolis, MN; Angela C. Hirbe, MD, PhD, Washington University School of Medicine in St Louis, St Louis, MO; Laura J. Klesse, MD, PhD, University of Texas Southwestern/Children's Health, Dallas, TX; P. Leia Nghiemphu, MD, University of California Los Angeles (UCLA), Los Angeles, CA; Dusica Babovic-Vuksanovic, MD, Mayo Clinic, Rochester, MN; and Timothy R. Gershon, MD, PhD, Department of Pediatrics, Emory University, Atlanta, GA.
出版信息
J Clin Oncol. 2025 May 20;43(15):1844-1846. doi: 10.1200/JCO-25-00308. Epub 2025 Mar 19.
Abstract
摘要
相似文献
1
Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.回复：1型神经纤维瘤病丛状神经纤维瘤临床试验中疗效评估的挑战
J Clin Oncol. 2025 May 20;43(15):1844-1846. doi: 10.1200/JCO-25-00308. Epub 2025 Mar 19.
2
A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1.一项关于丛状神经纤维瘤对1型神经纤维瘤病成人需求满足影响的定性研究。
SAGE Open Med. 2019 Feb 11;7:2050312119829680. doi: 10.1177/2050312119829680. eCollection 2019.
3
Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1.1型神经纤维瘤病患者丛状神经纤维瘤中生长激素受体的鉴定
Clinics (Sao Paulo). 2008 Feb;63(1):39-42. doi: 10.1590/s1807-59322008000100008.
4
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.评估 1 型神经纤维瘤病临床试验中丛状和皮肤神经纤维瘤相关外观问题的建议。
Clin Trials. 2024 Feb;21(1):6-17. doi: 10.1177/17407745231205577. Epub 2023 Dec 23.
5
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can't be removed by surgery, and impact on how the condition affects caregivers: a plain language summary.司美替尼用于无法通过手术切除的1型神经纤维瘤病和丛状神经纤维瘤患儿，以及该病症对护理人员的影响：通俗易懂的总结。
J Comp Eff Res. 2025 Mar;14(3):e240184. doi: 10.57264/cer-2024-0184. Epub 2025 Jan 21.
6
Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview.1型神经纤维瘤病患儿丛状神经纤维瘤的治疗：综述
J Child Neurol. 2002 Aug;17(8):638-41; discussion 646-51. doi: 10.1177/088307380201700816.
7
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
J Clin Oncol. 2025 May 20;43(15):1843-1844. doi: 10.1200/JCO-24-02733. Epub 2025 Mar 19.
8
Surgical Treatment and Complications of Deep-Seated Nodular Plexiform Neurofibromas Associated with Neurofibromatosis Type 1.1型神经纤维瘤病相关深部结节状丛状神经纤维瘤的外科治疗及并发症
J Clin Med. 2022 Sep 26;11(19):5695. doi: 10.3390/jcm11195695.
9
Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.1型神经纤维瘤病相关丛状神经纤维瘤中杂合性缺失的机制
J Invest Dermatol. 2009 Mar;129(3):615-21. doi: 10.1038/jid.2008.274. Epub 2008 Sep 18.
10
Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis.CCN1/CYR61、CCN3/NOV、CCN4/WISP1 和 CCN5/WISP2 在 1 型神经纤维瘤病肿瘤发生中的差异表达。
J Neuropathol Exp Neurol. 2010 Jan;69(1):60-9. doi: 10.1097/NEN.0b013e3181c79bff.
本文引用的文献
1
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
J Clin Oncol. 2025 May 20;43(15):1843-1844. doi: 10.1200/JCO-24-02733. Epub 2025 Mar 19.
2
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.ReNeu：米哚妥林治疗有症状的1型神经纤维瘤病相关丛状神经纤维瘤成人和儿童的关键IIb期试验
J Clin Oncol. 2025 Feb 20;43(6):716-729. doi: 10.1200/JCO.24.01034. Epub 2024 Nov 8.
3
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.在一项用于不可切除丛状神经纤维瘤的 1/2 期试验中，塞来替尼在儿童 1 型神经纤维瘤病中的长期安全性和疗效。
Neuro Oncol. 2023 Oct 3;25(10):1883-1894. doi: 10.1093/neuonc/noad086.
4
Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature.与非对照肿瘤试验中设盲的独立中央审查相比，本地研究者显著高估了总体缓解率：文献综述
Front Pharmacol. 2022 May 16;13:858354. doi: 10.3389/fphar.2022.858354. eCollection 2022.
5
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.NF106：神经纤维瘤病临床试验联盟的一项 II 期试验，评估 MEK 抑制剂 Mirdametinib（PD-0325901）在 NF1 相关丛状神经纤维瘤的青少年和成人患者中的疗效。
J Clin Oncol. 2021 Mar 1;39(7):797-806. doi: 10.1200/JCO.20.02220. Epub 2021 Jan 28.
6
Selumetinib in Children with Inoperable Plexiform Neurofibromas.索拉非尼治疗不可手术的丛状神经纤维瘤患儿的疗效观察。
N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18.
7
Recommendations for imaging tumor response in neurofibromatosis clinical trials.神经纤维瘤病临床试验中肿瘤反应的影像学推荐建议。
Neurology. 2013 Nov 19;81(21 Suppl 1):S33-40. doi: 10.1212/01.wnl.0000435744.57038.af.
8
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.在晚期癌症患者中进行口服 MAPK/ERK 激酶抑制剂 PD-0325901 的 I 期药代动力学和药效学研究。
Clin Cancer Res. 2010 Mar 15;16(6):1924-37. doi: 10.1158/1078-0432.CCR-09-1883. Epub 2010 Mar 9.
9
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging.利用磁共振成像对1型神经纤维瘤病中的丛状神经纤维瘤进行自动检测和体积测量。
Comput Med Imaging Graph. 2004 Jul;28(5):257-65. doi: 10.1016/j.compmedimag.2004.03.002.
Zotero 插件